Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31758003 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL7381169 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL22139321 | 0.86 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2KMT2ANPC1ALDH1A1 | |
| SCHEMBL20256229 | 0.86 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2KMT2ANPC1ALDH1A1 | |
| SCHEMBL29039375 | 0.85 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2KMT2ANPC1ALDH1A1 | |
| SCHEMBL26999281 | 0.85 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2KMT2ANPC1ALDH1A1 | |
| SCHEMBL29410731 | 0.85 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2KMT2ANPC1ALDH1A1 | |
| SCHEMBL31351949 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL25215473 | 0.84 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL19637426 | 0.84 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| WO-2005037828-A1 | NOVEL INHIBITORS OF DPP-IV, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP3, DPP7, DPP9 | HSD17B10 148/4885SMN1; SMN2 1910/4885KMT2A 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.